Core Viewpoint - The company reported a decline in net profit for the first half of 2025, while continuing to expand its research pipeline in children's medicine, chronic disease drugs, and innovative drugs [1][2]. Group 1: Financial Performance - In the first half of 2025, the company achieved an operating income of 584 million yuan, with a net profit attributable to shareholders of -73.54 million yuan [1]. - The company's self-research investment was approximately 94.21 million yuan, accounting for 16.14% of its operating income [2]. Group 2: Product Development and Approvals - The company obtained 10 new registration certificates, maintaining a leading position in the pharmaceutical industry for new approvals [2]. - The company has a total of 200 drug registration certificates, including 87 national medical insurance varieties and 26 national basic drug varieties [2]. - In addition to children's and chronic disease drugs, the company also received approvals for 5 new products in other therapeutic areas [3]. Group 3: Innovative Drug Development - The innovative drug AR882, a selective uric acid transporter (URAT1) inhibitor, has shown significant progress in clinical trials, with all participants enrolled in the global phase III trials [4]. - AR882 has demonstrated superior efficacy and safety compared to existing therapies for gout patients, with significant reductions in uric acid levels and gout stone burden [4]. - The company acquired 100% domestic rights to AR882 by purchasing a minority stake from a subsidiary, enhancing its competitive advantage [5].

自愿披露关于痛风创新药 AR882 全球Ⅲ期临床试验完成全部受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1.公司合作在研的创新药 AR882 尚需在国内外开展Ⅲ期临床研究并经药品 审评部门审批通过后，方可上市销售,能否通过监管部门的最终批准、获批上市 及上市时间具有不确定性。AR882 目前尚未实现上市销售，未产生销售收入，对 公司近期业绩不会产生重大影响。 2.AR882 全球Ⅲ期临床试验进展对公司近期业绩不会产生重大影响。敬请广 大投资者理性投资，注意风险。 近日，一品红药业集团股份有限公司（以下简称"公司"）参股公司 Arthrosi Therapeutics,Inc.（以下简称"Arthrosi"）组织开展的 AR882（通用名：氘泊替 诺雷）胶囊用于治疗痛风和痛风石全球关键性Ⅲ期临床试验已完成全部受试者入 组。现将主要情况公告如下： 证券代码：300723 证券简称：一品红 公告编号：2025-056 一品红药业集团股份有限公司 公司始终秉承创新发展理念，坚持医药技术创新与高端药品研发，通过自主 研发、合资合作开 ...

智通财经APP讯，一品红(300723.SZ)发布2025年半年度报告，该公司营业收入为5.84亿元，同比减少 36.02%。归属于上市公司股东的净亏损为7354.22万元。归属于上市公司股东的扣除非经常性损益的净 亏损为1.08亿元。基本每股亏损为0.1628元。 2025上半年公司自主研发投入约9,420.10万元，占公司营业收入的16.14%。2025年至今公司新增产品注 册批件10个。 ...

一品红药业集团股份有限公司 按照《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》(证监会公告[2022]26 号文）及其他相关规定，公 司 2025 年半年度非经营性资金占用及其他关联资金往来情况如下表所示： 上市公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | | | | | | 单位：元 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 占用方与上 | 上市公司核 | | 2025 年半年度占 | | 2025 年半年度 | | | | | 非经营性资 | 资金占用方名称 | | 市公司的关 | 2025 年半年度期 算的会计科 | | 年度占用 用累计发生金额 | | 2025 年半年度期 偿还累计发生 | 占用形 | 占 | | 用性质 | | | | | | | | | | | | 金占用 | | | | 初占用资金余额 | | 资金的利 | | 末占用资金余额 | 成原因 | | | | | 联关系 | 目 | | （不含利息） | ...

证券代码：300723 证券简称：一品红 公告编号：2025-052 一品红药业集团股份有限公司 第四届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 一品红药业集团股份有限公司（以下简称"公司"）第四届董事会第十一次 会议于 2025 年 8 月 20 日 15：00 以现场结合通讯表决方式召开。本次会议通知 已于 2025 年 8 月 8 日以电话或电子邮件等方式向全体董事发出。会议由董事长 李捍雄先生主持，会议应到董事 5 人，实到董事 5 人。公司监事、高管列席会议。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法规以 及《一品红药业集团股份有限公司章程》的有关规定。 二、董事会会议审议情况 公司 2025 年半年度报告所载资料内容符合法律、行政法规、中国证券监督 管理委员会和深圳证券交易所的相关规定，报告内容真实、准确、完整，不存在 任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）上披露的 《2025 年 ...

证券代码：300723 证券简称：一品红 公告编号：2025-053 一品红药业集团股份有限公司 第四届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 一品红药业集团股份有限公司（以下简称"公司"）第四届监事会第十次会 议于 2025 年 8 月 20 日 15：30 以现场结合通讯表决方式召开。本次会议通知已 于 2025 年 8 月 8 日以电话或电子邮件等方式向全体监事发出。会议由监事会主 席黄良雯女士主持，会议应到监事 3 人，实到监事 3 人，公司高管列席会议。本 次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法规以及 《一品红药业集团股份有限公司章程》的有关规定。 二、监事会会议审议情况 监事会认为：公司董事会编制和审核的公司 2025 年半年度报告的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上市 公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）上披露 ...

格隆汇8月21日丨一品红(300723.SZ)公布2025年半年度报告，上半年公司实现营业收入5.84亿元，同比 下降36.02%；归属于上市公司股东的净利润-7354.22万元，同比盈转亏；归属于上市公司股东的扣除非 经常性损益的净利润-1.08亿元；基本每股收益-0.1628元。 ...

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first half of 2025 compared to the same period in 2024, indicating potential challenges in its financial performance and operational efficiency [1][2][3]. Financial Performance - Revenue for the reporting period was approximately 583.80 million yuan, down 36.02% from 912.52 million yuan in the previous year [1]. - The net profit attributable to shareholders was a loss of approximately 73.54 million yuan, a decrease of 258.30% compared to a profit of 46.46 million yuan in the same period last year [1]. - The net profit after deducting non-recurring gains and losses was approximately -108.20 million yuan, a decline of 410.19% from 34.88 million yuan [1]. - The net cash flow from operating activities was -17.63 million yuan, down 109.32% from 189.20 million yuan [1]. - Basic and diluted earnings per share were both -0.1628 yuan, a decrease of 258.21% from 0.1029 yuan [1]. - The weighted average return on equity was -3.99%, down 5.80% from 1.81% [1]. Asset and Equity Position - Total assets increased to approximately 4.98 billion yuan, up 13.10% from 4.40 billion yuan at the end of the previous year [2]. - The net assets attributable to shareholders decreased to approximately 1.81 billion yuan, down 3.47% from 1.88 billion yuan [3]. Important Developments - The company has made progress in its research and development projects, obtaining 10 drug registration certificates for 9 self-developed products as of the disclosure date [5][6]. - A subsidiary received a government subsidy of 50 million yuan, which has been received [6][7]. - The company’s subsidiary, Guangdong Ruishi Pharmaceutical Technology Co., Ltd., obtained a drug production license for raw materials [7].

Core Viewpoint - The company reported a significant decline in revenue and incurred a net loss for the first half of 2025, indicating potential challenges ahead for its financial performance [2] Financial Performance - The company's operating revenue for the first half of 2025 was approximately 584 million yuan, representing a year-on-year decrease of 36.02% [2] - The net profit attributable to shareholders of the listed company was a loss of approximately 73.54 million yuan [2] - The basic earnings per share showed a loss of 0.1628 yuan [2]

上市公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 一品红药业集团股份有限公司 单位：元 | 非经营性资 | | | | 占用方与上 | 上市公司核 | 2025 | 年半年度期 | 2025 | 年半年度占 | 年半 2025 年度占用 | 年半年度 2025 | 2025 | 年半年度期 | 占用形 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 金占用 | | 资金占用方名称 | | 市公司的关 | 算的会计科 | | | | 用累计发生金额 | | 偿还累计发生 | 末占用资金余额 | | 成原因 | 占用性质 | | | | | | | 联关系 | 目 | 初占用资金余额 | | （不含利息） | | 资金的利 息（如有） | 金额 | | | | | | | 控股股东、实 | | | | | | | | | | | | | | | | | | 际 控 人 及 | 制 | | | | | | | | | ...